Sclc clinical trials

Explore recruiting sclc clinical trials.

Recruiting sclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Czechia, Austria, Spain, Germany, Netherlands, Latvia +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Treatment

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase IIIb study of durvalumab as consolidation treatment for patients diagnosed with limited stage small cell lung cancer who have not progressed following definitive concurrent or sequential platinum-based chemoradiation therapy in Spain (ALBORAN).

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Treatment Phase.

Germany, Spain, France, Austria, Belgium, Czechia +2 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

68Ga satoreotide trizoxetan PET/CT in patients with high grade neuroendocrine lung cancer

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)

Netherlands, Spain, Hungary, Finland, Romania, Italy +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Sclc trials by city

Sclc in Toronto Sclc in Vancouver Sclc in Montreal Sclc in Calgary Sclc in Edmonton Sclc in Ottawa Sclc in Winnipeg Sclc in Quebec City Sclc in Hamilton Sclc in Kitchener Sclc in London Sclc in Halifax Sclc in New York Sclc in Los Angeles Sclc in Chicago Sclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease